Colorectal Cancer

Cathy Eng, MD, FACP, FASCO, shares insights on biomarker testing and sequencing strategies for patients with colorectal cancer.

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.

GRANITE-based maintenance therapy improved PFS in first-line MSS colorectal cancer.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.

John H. Strickler, MD, highlights the mechanism of action of telisotuzumab adizutecan and the rationale for targeting c-Met in colorectal cancer.

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

A panel of clinicians in the CRC field discussed findings from pivotal clinical trials that were primarily shared during the 2024 ASCO Annual Meeting.

Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.

The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

The MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers.

The combination of favezelimab and pembrolizumab failed to improve OS vs regorafenib or TAS-102 in pretreated patients with PD-L1–positive, MSS mCRC.

Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.

The CAR T-cell therapy GCC19CART was safe and showed clinical activity in relapsed/refractory metastatic colorectal cancer.

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.